CP-25 inhibits PGE2-induced angiogenesis by down-regulating EP4/AC/cAMP/PKA-mediated GRK2 translocation

Clin Sci (Lond). 2020 Feb 14;134(3):331-347. doi: 10.1042/CS20191032.

Abstract

G protein-coupled receptor kinase 2 (GRK2), a type of cytosolic enzyme, transiently translocates to the plasma membrane upon G protein-coupled receptors (GPCRs) activation, and it also binds to extracellular signal-regulated kinase (ERK) to inhibit the activation of ERK. GRK2 deficiency in endothelial cells (ECs) leads to increased pro-inflammatory signaling and promotes recruitment of leukocytes to activated ECs. However, the role of GRK2 in regulating angiogenesis remains unclear. Here, we show that GRK2 is a novel regulatory molecule on migration and tube formation of ECs, vessel sprouting ex vivo and angiogenesis in vivo. We identify that EP4/AC/cAMP/protein kinase A (PKA)-mediated GRK2 translocation to cells membrane decreases the binding of GRK2 and ERK1/2 to inhibit ERK1/2 activation, which promotes prostaglandin E2 (PGE2)-induced angiogenesis. GRK2 small interfering RNA (siRNA) inhibits the increase in PGE2-induced HUVECs migration and tube formation. In vivo, PGE2 increases ECs sprouting from normal murine aortic segments and angiogenesis in mice, but not from GRK2-deficient ones, on Matrigel. Further research found that Lys220 and Ser685 of GRK2 play an important role in angiogenesis by regulating GRK2 translocation. Paeoniflorin-6'-O-benzene sulfonate (CP-25), as a novel ester derivative of paeoniflorin (pae), has therapeutic potential for the treatment of adjuvant arthritis (AA) and collagen-induced arthritis (CIA), but the underlying mechanism of CP-25 on angiogenesis has not been elucidated. In our study, CP-25 inhibits the migration and tube formation of HUVECs, and angiogenesis in mice by down-regulating GRK2 translocation activation without affecting GRK2 total expression. Taken together, the present results revealed that CP-25 down-regulates EP4/AC/cAMP/PKA-mediated GRK2 translocation, restoring the inhibition of GRK2 for ERK1/2, thereby inhibiting PGE2-stimulated angiogenesis.

Keywords: CP-25; G protein coupled receptor kinase 2; Human umbilical vein endothelial cells; Prostaglandin E4 receptor; Rheumatoid arthritis; Soft regulation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenylyl Cyclases / metabolism
  • Animals
  • Arthritis, Experimental / pathology
  • Arthritis, Rheumatoid / pathology
  • Cell Membrane / metabolism
  • Cell Movement / drug effects
  • Cell Proliferation / drug effects
  • Cyclic AMP / metabolism*
  • Cyclic AMP-Dependent Protein Kinases / metabolism*
  • Dinoprostone / pharmacology*
  • Down-Regulation / drug effects*
  • G-Protein-Coupled Receptor Kinase 2 / metabolism*
  • Glucosides / pharmacology*
  • HEK293 Cells
  • Human Umbilical Vein Endothelial Cells / drug effects
  • Human Umbilical Vein Endothelial Cells / metabolism
  • Humans
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Models, Biological
  • Monoterpenes / pharmacology*
  • Neovascularization, Physiologic / drug effects*
  • Phenotype
  • Protein Transport / drug effects
  • Rats
  • Receptors, Prostaglandin E, EP4 Subtype / metabolism*
  • Signal Transduction / drug effects
  • Synovial Membrane / drug effects
  • Synovial Membrane / pathology

Substances

  • Glucosides
  • Monoterpenes
  • Receptors, Prostaglandin E, EP4 Subtype
  • paeoniflorin-6'-O-benzenesulfonate
  • Cyclic AMP
  • Cyclic AMP-Dependent Protein Kinases
  • G-Protein-Coupled Receptor Kinase 2
  • Adenylyl Cyclases
  • Dinoprostone